CCO Independent Conference Coverage
2007 Annual Meeting of the American Association for the Study of Liver Diseases*
November 2-6, 2007 | Boston, Massachusetts
*CCO is an independent medical education company that provides state-of-the-art
medical information to healthcare professionals through conference coverage and other educational programs.
Clinical Updates in HBV Treatment
|
Track 1 of 4
|
|
|
|
   |
- Emmet B. Keeffe, MD, MACP
- Fred Poordad, MD
- Paul Martin, MD
|
|
|
Advances in HCV Management Strategies With Approved Agents
|
Track 2 of 4
|
|
|
|
   |
- Raymond T. Chung, MD
- Mitchell L. Shiffman, MD
- Mark S. Sulkowski, MD
|
|
|
Update on Investigational Agents in HCV: 2007
|
Track 3 of 4
|
|
|
|
   |
- Nezam H. Afdhal, MD, FRCPI
- Ira M. Jacobson, MD
- David R. Nelson, MD
|
|
|
Highlight on Special Hepatic Issues and Populations
|
Track 4 of 4
|
|
|
|
   |
- Robert J. Fontana, MD
- Stephen A. Harrison, MD, LTC, MC
- David L. Thomas, MD, MPH
|
|
|
CCO Expert Highlights
Listen to the experts quickly summarize the key issues in viral liver disease highlighted at the conference!
These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged on to the clinicaloptions.com site to listen to or download the mp3 files.
|
Nezam H. Afdhal, MD, FRCPI, discusses the key studies on investigational anti-HCV agents from the Boston meeting, focusing on specifically targeted small-molecule agents and an antiparasitic demonstrating anti-HCV activity. (7 minutes)
|
 |
Download Audio |
|
Raymond T. Chung, MD, reports on the most important presentations from Boston concerning predicting response to approved HCV agents and improving response of patients with poor probability of achieving sustained virologic response. In addition, he summarizes several studies of retreatment strategies for previous nonresponders. (11 minutes)
|
|
Download Audio |
|
Stephen A. Harrison, MD, LTC, MC, reviews key presentations from the Boston meeting related to insulin resistance, steatosis, and nonalcoholic steatohepatitis and their roles in the treatment of HCV. (9 minutes)
|
|
Download Audio |
|
Emmet B. Keeffe, MD, MACP, discusses several topics of interest in the field of HBV treatment, in particular, data on the use of tenofovir for the treatment of chronic HBV therapy and long-term efficacy of entecavir and baseline predictive factors for long-term treatment efficacy of telbivudine. (11 minutes)
|
|
Download Audio |
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|